Could an arthritis drug help rare lung disease patients?
NCT ID NCT07662265
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether tocilizumab, a drug already used for arthritis, can help people with a rare autoimmune lung condition called anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD) that hasn't responded to standard treatments. Researchers reviewed medical records of 111 patients treated between 2020 and 2025, comparing those who got tocilizumab to those on usual care. The goal was to see if tocilizumab improved symptoms, lung scans, and breathing tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tocilizumab (a drug that blocks IL-6, a protein involved in inflammation and scarring)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-control lung disease caused by anti-synthetase syndrome.
- What could go wrong
- This is a small, single-center retrospective study, not a large randomized trial. Results may not apply to all patients, and tocilizumab has known risks like serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTISYNTHETASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted immune drug calm rare muscle inflammation?
- Blood cell count may reveal who faces worst outcomes in rare autoimmune disease
- Engineered immune cells take aim at autoimmune diseases
- New hope for myositis: early IVIg may boost recovery
- Immune system overhaul: could CAR T-Cells tame autoimmune disease?
- New hope for rare lung disease: JAK inhibitors vs standard care